SLDB — Solid Biosciences Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1707502 ·
Last close
$6.82
Market Cap
$731.28M
52W High
$11.45
52W Low
$3.79
ADV30
1,230,004
Next earnings
2026-11-02
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -57,384,000 | -54,799,000 | 420,580,000 | 159,394,000 | 46,505,000 |
| Mar 2026 | 0 | — | -57,308,000 | -56,737,000 | 422,893,000 | 297,099,000 | 48,761,000 |
| Dec 2025 | 0 | — | -49,403,000 | -49,787,000 | 232,540,000 | 59,900,000 | 52,530,000 |
| Sep 2025 | 0 | — | -48,058,000 | -45,776,000 | 273,914,000 | 61,364,000 | 55,966,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-186,844,000
Investing CF
$-87,090,000
Financing CF
$293,817,000
CapEx
$-965,000
Dividends Paid
—
Buybacks
$-13,644,000
EPS Diluted TTM
$-1.80
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,069,311,000
Inventory
—
Receivables
—
ST Investments
$218,284,000
EBIT TTM
$-208,997,000
Pretax Income TTM
$-207,099,000
Interest Exp TTM
$128,000
Analysts
11
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -179,206,000 | -174,325,000 | 232,540,000 | 52,530,000 | 180,010,000 | -156,289,000 |
| Dec 2024 | 0 | -129,728,000 | -124,697,000 | 188,662,000 | 51,416,000 | 137,246,000 | -100,012,000 |
| Dec 2023 | 0 | -104,315,000 | -96,015,000 | 164,939,000 | 38,458,000 | 126,481,000 | -94,180,000 |
| Dec 2022 | 8,094,000 | -99,274,000 | -85,981,000 | 260,252,000 | 48,586,000 | 211,666,000 | -97,977,000 |
TTM Snapshot
Revenues TTM
$9,668,000
NetIncome TTM
$-191,780,000
OpCashFlow TTM
—
Assets (Latest)
$422,893,000
Forward EPS
$-1.75
Max Pain — expiry 2026-12-18
max pain strike: $7.00 · spot: $6.87 · call oi: 1,230 · put oi: 22
Expected Move to 2026-12-18:
±$3.35
(48.76%) —
implied range
$3.52 –
$10.22
· ATM straddle on $7.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CADL | Candel Therapeutics, Inc. | $739.17M | $9.66 | — |
| ATTO | Attovia Therapeutics, Inc. | $744.57M | $16.31 | — |
| FDMT | 4D Molecular Therapeutics, Inc. | $701.60M | $12.70 | — |
| AURA | Aura Biosciences, Inc. | $674.60M | $6.51 | — |
| PRME | Prime Medicine, Inc. | $649.33M | $3.58 | — |
News headlines (Yahoo Finance, 1h cache)
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-01 20:05 · Yahoo
Solid Biosciences to Participate at Upcoming Investor Conferences
2026-09-02 12:00 · Yahoo
Does Solid Biosciences' (SLDB) Russell Growth Index Debut Reveal a Shift in Its Investor Base?
2026-07-02 03:28 · Yahoo
Solid Biosciences and NanoMosaic Announce Co-Marketing Agreement to Advance Gene Therapy Delivery and Analytics
2026-06-02 11:00 · Yahoo
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-12 20:08 · Yahoo
Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy
2026-04-30 12:00 · Yahoo
Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy
2026-04-28 12:00 · Yahoo
Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy
2026-05-07 12:00 · Yahoo
Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-08-06 20:08 · Yahoo
Sarepta's Elevidys Showing Signs of Stabilization as siRNA Pipeline Gains Importance, RBC Says
2026-06-18 15:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.